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Abstract
Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at
critical tumor suppressor genes, such as p53, and increase breast cancer risk by either increasing
the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed
polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor
samples. Approximately 11% of patients exhibited mutations in p53. Women with mutations had a
significantly younger age of diagnosis (P = 0.01) and a greater incidence of tumors classified as
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stage II or higher (P = 0.002). More women with mutations had a history of smoking (55%)
compared to women without mutations (39%). Although none of the genotypes alone were
associated with p53 mutations, positive smoking history was associated with p53 mutations in
women with the GSTM1 null allele [OR = 3.54; 95% CI = 0.97–12.90 P = 0.06] compared to
women with the wild-type genotype and smoking history [OR = 0.62, 95% CI = 0.19–2.07],
although this association did not reach statistical significance. To test for gene–gene interactions,
our exploratory analysis in the Caucasian cases suggested that individuals with the combined
GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were more likely to harbor
mutations in p53 [OR = 4.94; 95% CI = 1.11–22.06]. Our results suggest that gene–smoking and
gene–gene interactions may impact the prevalence of p53 mutations in breast tumors. Elucidating
the etiology of breast cancer as a consequence of common genetic polymorphisms and the
genotoxic effects of smoking will enable us to improve the design of prevention strategies, such as
lifestyle modifications, in genetically susceptible subpopulations.
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INTRODUCTION
Breast cancer is the second leading cause of cancer-related deaths among women in the
United States [1]. Some of the known risk factors for breast cancer include previous biopsy,
radiation therapy, family history, and reproductive history, but these factors may account for
only half of the diagnosed breast cancer cases [2]. Although the etiological factors that
determine breast cancer incidence have not been completely identified, it is clear that both
environmental and genetic factors play a role in breast carcinogenesis.
In vitro and in vivo animal studies provided evidence that exposure to environmental
contaminants and/or endogenous estrogen could potentially lead to the development of
breast cancer [3-5]. Li et al. [6] demonstrated that aromatic DNA adducts were found more
frequently in the normal adjacent tissues of breast cancer cases than in a cancer free control
population, supporting the contribution of environmental contaminants to breast cancer risk.
The contribution of smoking to breast cancer is an area of controversy, as there is a potential
anti-estrogenic effect attributed to smoking [7]. However, a review of the literature
regarding smoking and breast cancer would suggest that smoking is unlikely to be protective
[8]. A recent cohort study supports the association of smoking with breast cancer [9], and
the Carolina Breast Cancer Study found mutations in p53 more frequently in current
smokers than non-smokers [10].
Potential breast carcinogens are not limited to exogenous compounds; endogenous estrogen
may also be a factor in breast carcinogenesis. Several known risk factors are related to
overall lifetime exposure to estrogen, such as early menarche or late menopause, as well as
obesity [11], which is linked to extra-ovarian estrogen production [12]. Estrogen can
stimulate cellular proliferation [13] as well as induce DNA damage following metabolism to
the catecholestrogens and the 3,4-hydroxycatecholestrogen quinone (CE-3,4-Q), which can
form depurinating adducts as well as generate reactive oxygen species [14,15].
Both exogenous and endogenous chemicals require metabolic activation by the phase I
cytochrome P450 (CYP450) enzymes in order to cause DNA damage. If the reactive
metabolites produced during phase I metabolism are not detoxified by phase II enzymes,
such as the glutathione S-transferases (GSTs), permanent genetic damage may occur. This
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suggests that an individual’s ability to metabolize exogenous and endogenous carcinogenic
agents may influence their risk for breast cancer.
CYP1B1 is expressed in both normal and cancerous breast tissue [16] and is capable of
activating a broad range of potentially carcinogenic substrates, including PAHs [17] and
estrogen [18]. The 4-hydroxylation of estrogen by CYP1B1 appears to be the predominant
hydroxylation pathway and results in the formation of a potentially carcinogenic
catecholestrogen metabolite [19]. Single nucleotide polymorphisms (SNPs) in exon 2
(A119S) and in exon 3 (L432V) have been shown to alter the enzyme’s metabolic
capabilities [16,20]. It has been suggested that the 432 V allele increases the catalytic
activity of CYP1B1 [20] as well as the ratio of the 4-OH to 2-OH catecholestrogen
metabolites produced [21,22], although others have found either no effect of the SNP on
enzyme activity or suggested that the 432 L allele actually increased catalytic activity [16].
Polymorphisms have also been identified in GSTs. Both GSTM1 and GSTT1 are deleted in
individuals with the respective null alleles [23], which may prevent detoxification of
activated substrates. PAHs, such as those found in cigarette smoke, are known substrates of
GSTM1, therefore, an absence of the enzyme could be a disadvantage in the detoxification
of these carcinogens [24]. The predominant GST in breast tissue [25], GSTP1, has two
functional SNPs located at codons 105 and 114, which result in amino acid substitutions of
I105V and A114V [23]. These SNPs influence enzyme activity depending on the substrate
being metabolized [23]. Although GSTP1 is also believed to conjugate GSH with the
catecholestrogen quinone [26], the impact of the SNPs on this metabolism has not been
determined.
The association of these polymorphisms and breast cancer risk has been analyzed in multiple
studies. Some studies have found associations between breast cancer risk and either
individual genotypes alone or when interacting with other risk factors [27-31], with few
analyzing the GSTP1 A114V SNP [32]. However, other studies have not confirmed these
associations [33-35]. These conflicting outcomes may be because of the heterogeneity of
women in breast cancer populations, as breast cancer in each individual patient likely results
from the interaction of different environmental and genetic factors. Few attempts have been
made to compare the frequency of occurrence and types of mutations observed at critical
oncogenic loci with the ability of breast tissue to metabolize chemical carcinogens. In this
regard, studies in a Japanese lung cancer population have found associations with SNPs such
as the I462V or MspI SNPs of the CYP1A1 gene and the incidence of p53 mutations in the
lung tumor tissue [36]. The p53 gene is a critical tumor suppressor gene [37] that is mutated
in 15–30% of breast cancer cases [38] and has been associated with a poorer prognosis and a
shorter survival time [39]. In breast cancer patients, both Nedelcheva Kristensen et al. [40]
and Gudmundsdottir et al. [41] suggested that mutations in the p53 gene were associated
with polymorphisms in the GST enzymes. We have thus hypothesized that patients
exhibiting mutations in p53 are more likely to be inherently susceptible to environmental
and endogenously produced toxicants because of their genetically determined ability to
metabolize carcinogens, which would result in elevated levels of activated carcinogenic
metabolites.
We conducted a case-only study to test the hypothesis that women with polymorphisms in
the phase I enzyme, CYP1B1, and phase II enzymes, GSTM1, GSTT1, and GSTP1, will be
at increased risk for a mutation in p53. As damage at tumor suppressor loci may contribute
to poor prognosis, these studies may allow for the early identification of the subset of
patients at increased risk for alterations to key regulatory genes whose products contribute
adversely to the patho-biology of breast cancer.
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The patient population used in this study is similar to the one described in a previous study
[42]. Breast cancer cases were recruited chiefly at the Breast Care Center at the Wake Forest
University Baptist Medical Center, with some samples also provided by the Moses H. Cone
Memorial Hospital and the University of North Carolina-Chapel Hill Lineberger
Comprehensive Cancer Center, from ongoing studies conducted from November 1998 to
May 2004. The study subjects were at least 18 yr of age, able to speak English and
comprehend informed consent, and did not have a previous history of cancer. Each of the
study subjects was given a detailed description of the study protocol and signed informed
consent as approved by each institution’s Institutional Review Board. A 20 ml blood sample
was collected from all study subjects along with a self-administered questionnaire
containing demographic information, established breast cancer risk factors, medical history,
and family history. For each case participant, paraffin embedded breast tumor or the lymph
node, if available, was retrieved for p53 mutation analysis.
Genotyping
DNA, which was used both for genotyping polymorphisms in the drug metabolic enzymes
and as matched controls in the p53 mutation analysis, was isolated from 200 μl of the blood
sample donated by each participant using the QIAamp® DNA Blood Mini Kit (Qiagen,
Valencia, CA), as described in the manufacturer’s protocol. For the breast cancer cases that
lacked a blood sample, DNA was extracted from the normal appearing tissue on the slides
prepared from the paraffin embedded tumor tissue obtained for that patient. DNA was
isolated using a digestion buffer consisting of 400 μg/ml proteinase K, 1% Tween-20, and
TE buffer (10 mM Tris-HCl, 0.1 mM EDTA). For the samples obtained from UNC, matched
DNA samples were obtained from lymphoblastoid cell lines that had been established from
the same patients, as described previously [43].
Genotyping of GSTM1 and GSTT1 were determined using a modification of a previously
described multiplex polymerase chain reaction (PCR) technique [44,45]. The PCR products
were analyzed for the presence or absence of the 480 bp GSTT1 and 231 bp GSTM1 PCR
products, with the 158 bp GSTM4 product serving as the internal control. For samples
requiring the use of paraffin embedded tissue (PET) and some blood samples, the GSTM1
primers were used along with a previously described GSTT1 and β-globin primer set [46,47]
(Table 1), resulting in PCR products of GSTM1: 231 bp, GSTT1: 111 bp, and β-globin: 268
bp.
Genotyping of the GSTP1 I105V SNP was determined using PCR followed by restriction
fragment length polymorphism. The GSTP1 I105V PCR product was digested in a 30 μl
reaction containing 20 U of BsmB1 (NE Biolabs, Beverly, MA) and 1× NE Buffer 3 (100
mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol). PCR products were
analyzed for either the wild-type 166 bp fragment or variant 94 and 72 bp fragments. The
CYP1B1 A119S and L432V and GSTP1 A114V genotypes were analyzed using a
previously described PCR-SSCP technique [48] adopted for use with the GenePhor
Electrophoresis System (conditions in Table 1). The PCR reaction mixtures were similar for
each gene/exon: 2.5 mM MgCl2, 0.2 mM (0.25 mM for the GSTM1/T1 analyses from PET)
dNTP mix (Promega, Madison, WI), 0.2 μM of each primer, 1–2 U of either AmpliTaq
Polymerase Gold (Applied Biosystems, Foster City, CA) or Taq DNA polymerase
(Eppendorf, Westbury, NY) with the manufacturer’s supplied buffer mix, and 2 μl of
template DNA.
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Further into the study, genotyping for the CYP1B1 and GSTP1 SNPs was completed with
the assistance of the Wake Forest University School of Medicine Center for Human
Genomics using MALDI-TOF mass spectrometry MASSArray® (Sequenom®, San Diego,
CA) as well as by sequencing with the assistance of either the Wake Forest University
School of Medicine Biomolecular Resources Facility DNA Sequencing Core or MWG-
Biotech, Inc. (High Point, NC).
For all of the assays utilized to determine SNPs in CYP1B1 and the GSTs, initial
experiments using either cell lines or tissues containing known SNPs were performed and
the resulting gene products sequenced to verify that the assays could accurately determine
the individual SNPs in each gene/exon.
p53 Mutation Analysis
Multiple 5 μm sections were cut from each of the PET samples. The investigator, along with
the collaborating pathologist, extensively reviewed H&E stained slides prior to
microdissection of the tissue sample. Each slide used in LCM was deparaffinized and
stained using a modification of an H&E staining procedure defined by the National Institute
of Environmental Health Sciences (NIEHS, dir.niehs.nih.gov/dirlep/lcm/protocols.html) for
use in LCM. The deparaffinized slide was then microdissected using the PixCell II
Microdissection Station (Arcturus, Mountain View, CA) with the CapSure™ Macro LCM
caps (Arcturus). The cells were digested and released from the caps by incubating overnight
at 37°C in an incubator with a digestion buffer consisting of 400 μg/ml proteinase K, 1%
Tween-20, and TE buffer (10 mM Tris-HCl, 0.1 mM EDTA). Following overnight
digestion, the samples were heated to 95°C for 8 min to deactivate the proteinase K.
Multiple caps for each sample were collected if sufficient tissue was available.
Aliquots (5–10 μl) of the digest were utilized to amplify tumor DNA for two rounds of PCR
for exons 5–9 of the p53 gene using the nested primers listed in Table 2. The amplification
reaction mixture consisted of 2.5 mM MgCl2, 0.2 mM dNTP mix (Promega), 0.2 μM of
each of the forward and reverse primers, 4 U of either AmpliTaq Polymerase Gold (Applied
Biosystems) or Taq DNA polymerase (Eppendorf) with the manufacturer’s supplied buffer
mix, and 5–10 μl of digest. Following an initial denaturation step of either 2 (for Eppendorf
Taq) or 10 (AmpliTaq) minutes, DNA was amplified by 40 cycles of denaturation for 30 s at
94°C followed by 2 min of annealing (see Table 2 for temperatures) and extension at 72°C.
Primary PCR products were purified using the PerfectPrep® PCR Cleanup 96 Kit
(Eppendorf) prior to secondary amplification. The cycles were reduced to 25 and annealing
and extension times were shortened to 1 min for the secondary amplification reaction. Five
to ten microliters of primary or purified primary PCR product was used as template for the
secondary amplification. Amplification from the matched blood sample, which did not
require a secondary amplification reaction, utilized the secondary primer set and 40 cycles
of 30 s denaturation and 1 min annealing and extension.
The p53 PCR products were initially screened for mutations using single stranded
conformation polymorphism (SSCP) with the GenePhor flatbed electrophoresis system
(Amersham Biosciences, Piscataway, NJ). The denatured products were separated by
electrophoresis on the GenePhor system at the temperature predetermined for each exon and
using the recommended voltage and wattage described in the manufacturer’s protocol.
Following electrophoresis, the gel was stained with the Plus One DNA Silver Staining Kit
(Amersham Biosciences) according to the manufacturer’s protocol. All tumors exhibiting a
band shift were re-amplified and reanalyzed to confirm the shift and eliminate the possibility
of a Taq-induced error. All tumors exhibiting a repeated band shift were sequenced by either
the Wake Forest University School of Medicine Biomolecular Resources Facility DNA
Sequencing Core or MWG-Biotech, Inc. by either direct sequencing of the purified
Van Emburgh et al. Page 5













secondary PCR product or, as required, by isolating the PCR products from the SSCP gel,
precipitating, and re-amplifying from the eluted bands. Samples that were difficult to
interpret because of the presence of a heterozygous insertion or deletion were sequenced
following cloning of the PCR products using the TOPO TA® Cloning Kit (Invitrogen,
Carlsbad, CA). As more high-throughput technology became available, approximately one
third of the PCR products were screened for mutations as a contract service by
SpectruMedix L.L.C (State College, PA) by Reveal™ Temperature Gradient Capillary
Electrophoresis (TGCE) and samples analyzed by SpectruMedix using SpectruMedix
Analytical Software. As for the SNP assays, initial studies were conducted using either DNA
obtained from cell lines with known p53 mutations or patient samples to ensure the assays
could identify mutations—in these instances, samples were sequenced to confirm the results.
Statistical Analysis
The comparisons of categorical demographics between those women with and without p53
mutations were assessed using chi-square or Fisher exact tests. Wilcoxon rank-sum tests
were used to assess differences in continuous characteristics. Logistic regression was used to
estimate and assess the significance of the genotype effects after adjustment for patient
characteristics, including age, age of menarche, smoking history, and body mass index
(BMI). All two-way interactions between genotypes and effect modifiers were considered
initially, and a backwards stepwise algorithm was used to remove nonsignificant interactions
from the model (P > 0.05). Interactions with the highest P value were excluded first and the
model was repeated as described. Analyses were completed using the Statistical Analysis
System (SAS Institute, Cary, NC).
To test for high-order gene-gene interactions, the multivariate adaptive regression splines
(MARS)-logit model was utilized. The MARS-logit model [49] is a hybrid model that
combines MARS [50] and the traditional logistic model. The model is overfit followed by
dropping the terms that contribute the least to the model. The maximum number of basis
function is used to control how big the model is in the first step and the final size decided by
the degrees of freedom (df) charged per basis function. In this study, a 10-fold cross-
validation was used for MARS model selection. If the model selected by 10-fold cross-
validation was too small, three df were charged per basis function. We tested for 1-, 2-, and
3-way interactions.
In the MARS-logit hybrid model, MARS is applied as a variable screening tool and the
selected terms, and their extended terms, are plugged in a logistic regression model, which
has been described in Cook et al. [49]. Cook used forward-backward and backward-forward
automatic selection in logistic models; however, this study used backward first and then
dropped the insignificant variables. The BIC (Bayesian information criterion) [51] was used
as the criteria for final model selection as this discourages model overfitting by penalizing
models for adding variables and it is more conservative than Akaike information criterion.
SAS version 9.1 (SAS Institute) and commercial MARS software (Salford systems, San
Diego, CA) were used in this study.
RESULTS
Of the 323 (301 Caucasian, 22 African American) women analyzed for p53 mutations in this
study, 34 (11%) exhibited mutations in exons 5–9 of p53, which is less than the expected
15–30% reported previously in breast cancer patient populations [38]. Differences in
populations may contribute to the lower frequency observed in this study [52,53]. Two of
the women had more than one mutation (#3260 and #3854) and one woman had a complex
mutation that consisted of a single nucleotide mutation and insertion in tandem, making a
total of 36 mutations analyzed (see Table 3). As some of the women exhibited identical
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mutations, there are thirty different loci involved. Twenty-six of the 30 mutations were
single nucleotide mutations, three were small deletions, and one was the complex mutation
described above. Of the 26 single nucleotide mutations, 19 were missense mutations, four
were nonsense mutations, and three were intronic/splice site mutations. Two former and two
current smokers have deletions and complex mutations.
These mutations may impact protein function. The three deletions and the complex mutation
would result in either a frameshift (2 samples), a three base pair deletion (1 sample) found
between codons 253 and 254 (resulting in a loss of one amino acid), or as seen in the
complex mutation (1 sample) the introduction of a stop codon followed by a frame shift. The
four nonsense mutations would be expected to produce truncated proteins. Three of the
women had mutations in potential intronic splice sites; the functional significance of these
mutations is unknown.
Missense mutations were the predominant single nucleotide mutations found, consistent
with the results reported in the International Agency for Research on Cancer (IARC)
database [54]. The most common type of mutation found in this population is G:C → A:T,
which is also consistent with the most frequent type of mutation in breast cancer as
determined in the IARC database [54]. The missense mutations consisted of 19 different
amino acid substitutions at 16 different codons. Two different mutations occurred at codon
237 and three different mutations were seen at codon 248. Eight of the women in this study
had a mutation at codon 248, which is a known mutation hotspot in breast cancer [54].
Information contained in the IARC database indicates that some of these missense mutations
have functional implications in terms of protein function [54].
When the characteristics of the 34 women with a mutation in p53 were compared to women
without a mutation, age of diagnosis and stage of disease were significantly different (P =
0.01 and 0.002, respectively, Table 4). The women with a mutation had a significantly
younger age of diagnosis than those without a mutation [median age for wild-type = 59.9,
median age for mutant = 50.0] and were more likely to have stage II-IV disease (66.7%
compared to 39.0%). The association between smoking status (ever/never) and p53 status
was of borderline statistical significance (P = 0.08), as women with a p53 mutation tended to
have a history of smoking. However, p53 mutation status did not differ by race, BMI, family
history, current smoking status, age of menarche, parity, number of children, or age of first
live birth.
The association between polymorphisms in four phase I/II enzymes and p53 mutations was
evaluated. An univariate analysis found no association between p53 mutation status and
GSTM1 or GSTT1 null genotype (Supplemental Table 1). The crude OR analysis showed a
weak but not significant association between p53 mutation and the GSTP1 105 VV genotype
[OR = 1.47; 95%CI = 0.48–4.51]. The GSTP1 114 AV genotype appears to be somewhat
protective compared to the AA genotype [OR = 0.24; 95% CI = 0.05–1.18]. None of the
women in this study were homozygous for the GSTP1 114 VV allele, eliminating the
possibility of analyzing the impact when both alleles are variant. CYP1B1 A119S or L432V
genotype did not have an effect on p53 mutational status. The multivariable models revealed
significant interactions between GSTM1 and smoking history (P = 0.023) and between
GSTP1 I105V and age of menarche (P = 0.030).
As shown in Table 5, a slightly higher prevalence of p53 mutations was observed in breast
tumors from former (12.9%) or current smokers (15.4%) compared to that in never smokers
(8.1%). In general, smoking was associated with a higher but not significant prevalence of
p53 mutations [OR = 2.14, 95%CI = 0.82–5.57 for former smokers and OR = 1.09, 95%CI =
0.35–3.24 for current smokers]. Current smoking status was associated with a higher
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prevalence of transversion mutations in p53 [OR = 2.34, 95% = 0.46–11.85]. Furthermore,
smoking increased the odds of harboring a p53 mutation in women with the GSTM1 null
genotype [OR = 3.81; 95% CI = 1.03–14.12] compared to women with the GSTM1 positive
genotype [OR = 0.56; 95% CI = 0.17–1.80]. When these results were adjusted for stage, the
odds were still increased, but the interaction was only marginally significant [OR = 3.54;
95% CI = 0.97–12.90, P = 0.06] (Table 6). The other polymorphisms were not analyzed by
smoking status in detail as there were no significant interactions. The risk of having a p53
mutation increased as the age of menarche increased in women with at least one GSTP1 105
I allele (II/IV) [OR = 1.67; 95% CI = 1.24–2.24, P = 0.001] while the risk decreased as the
age of menarche increased in women who had the GSTP1 105 VV genotype [OR = 0.11;
95% CI = 0.01–1.06, P = 0.056].
Examining individual genotypes did not yield statistically significant associations with p53
mutations. Figure 1 presents an exploratory analysis into the impact of gene–gene
interactions on mutations using the MARS-logit technique. For this pilot study, we only
used the data from Caucasians, as significant interactions disappeared when data from
African-Americans were included. These results suggest that the combined genotypes of
GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were associated with
mutations in p53 [OR = 4.94; 95% CI = 1.11–22.06] compared with women with other
genotype patterns. As the sample size is small, it would be necessary to confirm these
interactions in a larger study, but it supports the importance of examining combinations of
genotypes when determining the impact of polymorphisms on mutations.
DISCUSSION
Since nearly half of all breast cancer cases diagnosed are of unknown etiology, it is
important to identify genetic risk factors involved in the etiology of sporadic breast cancer.
Multiple case/control studies analyzing associations between individual SNPs of phase I and
phase II enzymes and breast cancer risk have provided conflicting results [22-30]. Thus, we
utilized mutations at the p53 gene locus as a biomarker for patients susceptible to genetic
damage who may be more likely to exhibit associations between polymorphisms in drug
metabolic enzymes and breast cancer risk. For this study, exons 5–9 were analyzed for
mutations, as this region contains the DNA binding domain that is most frequently mutated
in human cancer [54,55].
Women that had a mutation in p53 exhibited a younger age of diagnosis than women
without a mutation. Age is a significant risk factor for breast cancer, as the risk has been
shown to increase as a woman gets older [11]. Interestingly, a younger age at diagnosis has
been associated with a poorer prognosis [56]. Thus, our results demonstrating that women
with mutations in p53 had a younger age of diagnosis suggest that genetic susceptibility to
mutation at oncogenic loci may result in earlier tumor onset in this susceptible sub-
population of women. In this regard, Sidoni et al. [57] showed that expression of p53 was
more frequent in younger populations, although an analysis of p53 mutations in a Brazilian
population of breast cancer cases did not confirm a difference in age between women with
and without mutations [53]. These disparate results could be because of different
environmental exposures or genetic factors between the two study populations. Women with
mutations also exhibited a higher stage disease, which has been observed in other studies
[10]. A recent study by Carey et al. [58] demonstrated a statistically significant difference in
p53 mutations in the more aggressive subtypes of breast cancer. An increased incidence of
p53 mutations in the younger women would be consistent with the more aggressive disease
and poorer outcome in terms of survival and prognosis.
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The results of this study suggest that smoking may contribute to a higher prevalence of p53
mutations (P = 0.08), which is consistent with a study showing that PAH adducts were seen
in breast cancer cases more frequently than controls [6]. As mentioned previously, the
Carolina Breast Cancer Study determined that current smokers had a significantly higher
mutation frequency in their breast tissue compared to never smokers (P = 0.02) [10]. This
suggests that even though smoking alone may not be directly associated with breast cancer
risk, it may be associated with the induction of mutations in tumor suppressor genes, which
could lead to more aggressive forms of the disease. While we found no effect of the GSTM1
null genotype on the p53 mutational status [OR = 0.90; 95% CI = 0.44–1.84], our results
demonstrated that the GSTM1 null allele was associated with an increase of p53 mutations
in women who smoked, although significance was marginal when adjusted for stage. This
may be because of the small number of samples with mutations. GSTM1 conjugates reactive
electrophilic compounds produced during phase I metabolism, thus deletion of the gene
would be expected to reduce the detoxification of carcinogenic metabolites found in
cigarette smoke. Previous studies support the association of GSTM1 null alleles with DNA
damage as these alleles have been associated with PAH adducts in cancer cases compared to
controls [59]. Consistent with this study, significant interactions have been noted with the
GSTM1 null alleles and smoking and their association with DNA adducts in the normal
adjacent tissue of breast cancer cases [60]. Similar interactions have also been noted with
alcohol consumption as well, supporting the importance of gene–environmental interactions
and using genetic markers [61].
Our analysis of individual SNPs and risk for breast cancer based on genetic damage at the
p53 gene locus did not demonstrate significant associations for any of the drug metabolic
polymorphisms analyzed. However, a previous study by Nedelcheva Kristensen et al. [40]
demonstrated an association between the GSTP1 105 IV/VV genotypes and p53 mutations
(P = 0.055). Gudmundsdottir et al. [41] also noted a nonsignificant but interesting trend for
the 105 VV genotype and having a mutation in p53 (P = 0.19) and a statistically significant
increase in the frequency of the GSTT1 null allele in breast cancer patients with a mutation
in p53 (P = 0.019). The differences between these studies and the current one may be
attributable to differences in the populations, as the patients were recruited in Norway [40]
and Iceland [41] compared to our North Carolina population. Differences in lifestyle could
result in differences in environmental exposures. Neither of the previous studies [40,41]
reported demographic information or made adjustments for potential confounders and effect
modifiers. Indeed, other studies have shown that the types of mutations found in p53 tend to
vary geographically [52], which suggests that differences in exposure to environmental
agents could impact the influence of polymorphisms on the generation of mutations.
With limited sample size, our results suggest that individual genetic polymorphisms in drug
metabolic enzymes may not influence the p53 mutational status of breast cancer patients.
However, we demonstrated marginally significant interactions between the GSTM1
genotype and smoking that influence the prevalence of p53 mutations. In addition, the
combined genotypes of GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 wild-type
exhibited an almost five-fold increase in risk of having a mutation in p53 in Caucasian
women. The CYP1B1 432 Leu allele has been associated with a lower level of B[a]P
induced DNA adducts supporting the effect of the polymorphism on carcinogen induced
DNA damage [62]. The association of the GSTM1 wild-type allele in the MARS-logit
model with breast cancer risk seems contrary to the results obtained with the smoking data
and ability of GSTM1 to detoxify toxic metabolites. GSTP1 is the most prevalent GST
found in breast tissue [31] and it is possible that, because of the specificity of the GSTs for
specific substrates, the presence of GSTM1 may inhibit the ability of GSTP1 to detoxify
specific xenobiotics because of glutathione depletion. This was suggested in a previous case/
control study which found an association between the homozygous wild-type alleles and
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breast cancer [63]. Alternatively, GSTM1 is also capable of forming more toxic compounds
from some substrates instead of detoxifying them [64]. The effect of smoking on gene–gene
interactions was not analyzed as the number of patients were too few to stratify by smoking
status. In the case of smokers, the high levels of exposure to toxic chemicals may
overwhelm the normal detoxification pathways, and GSTM1 would then play a more
protective role. Further studies utilizing animal models and cell culture systems are required
to determine the mechanisms of detoxification in smoking and non-smoking patients.
Our results suggest that future studies should focus on the combined effects of gene–gene
and gene–environmental interactions on the induction of p53 mutations, which will have a
significant impact on our understanding of genetics and gene–exposure interactions in breast
tumor progression. With the rapid development of high-throughput genotyping methods, we
are in an excellent position to rapidly translate genetic susceptibility information into health
behavior promotion, as genetically susceptible sub-populations are more motivated to
participate in behavior intervention, such as smoking cessation.
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Gene–gene interaction and p53 mutations. Exploratory analysis of combined genotypes and
p53 mutations. The reported odds ratio was adjusted for age, age at menarche, BMI, and
smoking status.
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Table 4
p53 Mutations by Personal Characteristics
Variable Categories Wild-type (N = 289) Mutant (N = 34) P-value
Race Caucasian 269 (93%) 32 (94%) 1
African-American 20 (7%) 2 (6%)
Age Mean (SD) 59.55 (12.51) 53.66 (13.16) 0.01 *
Median (Range) 59.90 (27.87–49.88) 49.95 (31.90–84.38)
Missing 0 0
Family history No (%) 209 (77%) 25 (78%) 0.9
Mother/sister (%) 62 (23%) 7 (22%)
Missing 18 2
Age menarche ≤12 136 (45.9%) 10 (13.3%) 0.11
13–14 12 (36.4%) 16 (48.5%)
15+ 39 (14.2%) 7 (21.2%)
Missing 17 1
Smoking history Never (%) 169 (61%) 15 (45%) 0.08
Ever (%) 107 (39%) 18 (55%)
Missing 13 1
Current smoker No (%) 236 (88%) 26 (81%) 0.28
Yes (%) 33 (12%) 6 (19%)
Missing 20 2
BMI Mean (SD) 27.61 (6.11) 25.71 (4.23) 0.18
Median (Range) 26.26 (16.97–58.39) 25.36 (18.72–36.04)
Missing 18 3
Number of children Mean (SD) 2.15 (1.43) 2.03 (1.47) 0.56
Median (Range) 2 (0–9) 2 (0–6)
Missing 12 1
Parity Nulliparous (%) 36 (13%) 5 (15%) 0.78
≥1 child (%) 241 (87%) 28 (85%)
Missing 12 1
Tumor stage
a 0–I 175 (61.0%) 11 (33.3%) 0.002 *
II –IV 112 (39.0%) 22 (66.7%)
Missing 5 1
Age at first live birth Mean (SD) 23.38 (4.73) 25.18 (6.17) 0.17
Median (Range) 23 (15.00–41.00) 25 (15.00–39.00)
Missing 15 1
a
According to the AJCC breast tumor staging guidelines.
*
Statistically significant at P< 0.05.
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Table 5
Association Between Smoking Status and p53 Mutations
# mutations/# Crude OR Adjusted OR
a
Smoking status tumors % (95% CI) (95% CI)
Any p53 mutation
 Never 15/185 8.1 Reference Reference
 Former 11/85 12.9 1.69 (0.74–3.84) 2.14 (0.82–5.57)
 Current 6/39 15.4 2.06 (0.75–5.70) 1.09 (0.35–3.24)
Transitions
 Never 10/185 5.4 Reference Reference
 Former 6/85 7.1 1.33 (0.47–3.79) 1.90 (0.59–6.13)
 Current 2/39 5.1 0.95 (0.20–4.50) 0.40 (0.07–2.21)
Transversions
 Never 5/185 2.7 Reference Reference
 Former 3/85 3.5 1.32 (0.31–5.64) 1.01 (0.17–5.87)
 Current 3/39 7.7 3.00 (0.69–13.12) 2.34 (0.46–11.85)
a
Adjusted for age, age of menarche, BMI, and tumor stage.
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Table 6
Interaction Between Smoking History and GSTM1 Genotype in p53 Mutations
Smoking p53 wild-type p53 mutant Adjusted OR
GSTM1 status n (%) n (%) (95%CI)
a
Wild-type Non-smoker 80 (59.3) 10 (58.8) Reference
Smoker 55 (40.7) 7 (41.2) 0.62 (0.19–2.07)
Null Non-smoker 90 (62.5) 5(31.3) Reference
Smoker 54 (37.5) 11 (68.7) 3.54 (0.97–12.90)
a
Adjusted for age, age of menarche, BMI, and tumor stage.
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